(Q37770555)

22 August 2017

1 reference

title

Clinical pharmacokinetics of therapeutic monoclonal antibodies (English)

1 reference

22 August 2017

1 reference

1 reference

1 reference

4

Jos H Beijnen

1 reference

22 August 2017

2

Alwin D R Huitema

1 reference

22 August 2017

3

Jan H M Schellens

1 reference

22 August 2017

Ron J Keizer

1

1 reference

22 August 2017

1 August 2010

1 reference

Clinical Pharmacokinetics

22 August 2017

1 reference

22 August 2017

49

1 reference

22 August 2017

493-507

1 reference

22 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.2165/11531280-000000000-00000

22 August 2017

0 references

cites work

Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11531280-000000000-00000

FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11531280-000000000-00000

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11531280-000000000-00000

Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes

21 January 2018

1 reference

12 December 2020

Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.

1 reference

12 December 2020

Production of recombinant protein therapeutics in cultivated mammalian cells

1 reference

12 December 2020

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

12 December 2020

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

12 December 2020

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

1 reference

12 December 2020

Receptors for the Fc portion of immunoglobulin G (Fc gamma R) on human monocytes and macrophages

1 reference

12 December 2020

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

12 December 2020

Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy

1 reference

12 December 2020

The transmission of immunity from mother to young and the catabolism of immunoglobulins

1 reference

12 December 2020

Antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

12 December 2020

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

1 reference

12 December 2020

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

1 reference

12 December 2020

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

12 December 2020

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

1 reference

12 December 2020

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

1 reference

12 December 2020

In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.

1 reference

12 December 2020

Oncotic pressure in solid tumors is elevated

1 reference

12 December 2020

Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

1 reference

12 December 2020

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

1 reference

12 December 2020

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

1 reference

12 December 2020

Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group

1 reference

12 December 2020

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

1 reference

12 December 2020

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

12 December 2020

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

1 reference

12 December 2020

Development of antibody fragments for immunotherapy of prion diseases.

1 reference

12 December 2020

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects

1 reference

12 December 2020

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

1 reference

12 December 2020

Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct

1 reference

12 December 2020

Development trends for monoclonal antibody cancer therapeutics.

1 reference

12 December 2020

Production technologies for monoclonal antibodies and their fragments

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments

1 reference

12 December 2020

Clinical immunotoxicity of therapeutic proteins

1 reference

12 December 2020

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

1 reference

12 December 2020

Immunogenicity of therapeutic proteins: clinical implications and future prospects

1 reference

12 December 2020

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

1 reference

12 December 2020

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

1 reference

12 December 2020

Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn

1 reference

12 December 2020

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease

1 reference

12 December 2020

Vascular and interstitial barriers to delivery of therapeutic agents in tumors

1 reference

12 December 2020

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

1 reference

12 December 2020

Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients

1 reference

12 December 2020

Potent antibody therapeutics by design

1 reference

12 December 2020

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

1 reference

12 December 2020

Metabolism of immunoglobulins

1 reference

12 December 2020

Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution

1 reference

12 December 2020

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

1 reference

12 December 2020

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

12 December 2020

Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys

1 reference

12 December 2020

Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study

1 reference

12 December 2020

Monoclonal antibody successes in the clinic

1 reference

12 December 2020

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

12 December 2020

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

1 reference

12 December 2020

Monoclonal and recombinant antibodies, 30 years after ...

1 reference

12 December 2020

Comparing antibody and small-molecule therapies for cancer

1 reference

12 December 2020

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

12 December 2020

Human antiglobulin response to foreign antibodies: therapeutic benefit?

1 reference

12 December 2020

In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab

1 reference

12 December 2020

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

12 December 2020

Early development of therapeutic biologics--pharmacokinetics.

1 reference

12 December 2020

Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series

1 reference

12 December 2020

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

1 reference

12 December 2020

Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

1 reference

12 December 2020

Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

12 December 2020

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

1 reference

12 December 2020

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

12 December 2020

Antibodies as carrier proteins

1 reference

12 December 2020

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

1 reference

12 December 2020

Rationales, evidence, and design considerations for fractionated radioimmunotherapy

1 reference

12 December 2020

Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

1 reference

12 December 2020

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

12 December 2020

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

12 December 2020

Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics

1 reference

12 December 2020

Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

1 reference

12 December 2020

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

12 December 2020

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

12 December 2020

Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice.

1 reference

12 December 2020

Suppression of Cytochrome P450- and UDP Glucuronosyl Transferase-Dependent Enzyme Activities by Proinflammatory Cytokines and Possible Role of Nitric Oxide in Primary Cultures of Pig Hepatocytes

1 reference

12 December 2020

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

12 December 2020

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

1 reference

12 December 2020

Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts

1 reference

12 December 2020

Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality

1 reference

12 December 2020

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

1 reference

12 December 2020

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.

1 reference

12 December 2020

How to predict and prevent the immunogenicity of therapeutic proteins

1 reference

12 December 2020

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

10.2165/11531280-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20608753

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20608753